Limits...
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus

The remove of the additive effect of sildenafil on top of Epoprostenol (PACE-1).164
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4352681&req=5

fig11: The remove of the additive effect of sildenafil on top of Epoprostenol (PACE-1).164

Mentions: The first Phase 3 clinical trial to address the combination therapy by adding sildenafil to the prostacyclin derivatives162,163 was the PACE-1 study (Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil).164 Prostacyclin derivatives were always considered the main therapy for pulmonary arterial hypertension. PACE-1 was designed to investigate the safety and efficacy of adding oral sildenafil to long-term intravenous epoprostenol treatment. It involved 267 patients with pulmonary arterial hypertension who were receiving long-term intravenous epoprostenol therapy. The patients were randomized to receive placebo or sildenafil 20 mg three times daily, titrated to 40 mg and 80 mg three times daily as tolerated, at 4-week intervals. 97% of the patients completed the study. The results showed that a placebo-adjusted increase of 28.8 meters (95% CI, 13.9 to 43.8 meters) in the 6-minute walking distance occurred in patients in the sildenafil group (Figure 11). These improvements were most prominent amongst patients with baseline distances of 325 meters or more. By the end of week 16, fewer patients in the sildenafil group compared to the placebo group had clinical worsening events. Furthermore, sildenafil resulted in a greater change in mean pulmonary arterial pressure by 3.8 mm Hg relative to epoprostenol monotherapy. Overall, the combination was well tolerated.164


The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

The remove of the additive effect of sildenafil on top of Epoprostenol (PACE-1).164
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4352681&req=5

fig11: The remove of the additive effect of sildenafil on top of Epoprostenol (PACE-1).164
Mentions: The first Phase 3 clinical trial to address the combination therapy by adding sildenafil to the prostacyclin derivatives162,163 was the PACE-1 study (Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil).164 Prostacyclin derivatives were always considered the main therapy for pulmonary arterial hypertension. PACE-1 was designed to investigate the safety and efficacy of adding oral sildenafil to long-term intravenous epoprostenol treatment. It involved 267 patients with pulmonary arterial hypertension who were receiving long-term intravenous epoprostenol therapy. The patients were randomized to receive placebo or sildenafil 20 mg three times daily, titrated to 40 mg and 80 mg three times daily as tolerated, at 4-week intervals. 97% of the patients completed the study. The results showed that a placebo-adjusted increase of 28.8 meters (95% CI, 13.9 to 43.8 meters) in the 6-minute walking distance occurred in patients in the sildenafil group (Figure 11). These improvements were most prominent amongst patients with baseline distances of 325 meters or more. By the end of week 16, fewer patients in the sildenafil group compared to the placebo group had clinical worsening events. Furthermore, sildenafil resulted in a greater change in mean pulmonary arterial pressure by 3.8 mm Hg relative to epoprostenol monotherapy. Overall, the combination was well tolerated.164

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus